Business Wire

FONDATION-IPSEN

Share
The 24th Colloque Médecine et Recherche in the Neurosciences Series of the Fondation Ipsen: “Genome editing in neurosciences”

A new method for making precise changes in selected genes is taking the world of biomedical research by storm. Known by the rather inelegant name of CRISPR-Cas9, it is a rapid, efficient, versatile and relatively cheap tool for dissecting the molecular pathways that are the basis of life, as well as for investigating and potentially rectifying faults in these pathways that result in disease. During this Colloque Médecine et Recherche in Neurosciences organized by the Fondation Ipsen, an international panel of speakers reviewed how this and other genome editing techniques are advancing understanding of the development and functioning of the nervous system. A special focus has been on the combination of genome editing with recent developments in stem cell technology, which is proving particularly powerful for uncovering the mechanisms of, and developing treatments for, a range of neurological disorders. The scientific committee included Rudolf Jaenisch (MIT, Cambridge, USA), Feng Zhang (MIT, Cambridge, USA), Fred Gage (Salk Institute for Biological Studies, La Jolla, USA) and Yves Christen (Fondation Ipsen, Paris, France).

Genes are the blueprints for making proteins, the complex molecules that provide both the structural and functional organisation of all forms of life. A mutation in a gene may result in the protein being misshapen, shortened or absent, causing a hiccup in a biological process that may cause disease or death. The roles of healthy or mutated proteins have been investigated for many years by studying what happens in the organism when single genes are silenced or their activity enhanced. Although used extensively and productively, these methods are cumbersome, expensive and not very reliable. In the past five years, a new generation of techniques have been developed that use enzymes known as endonucleases to make precisely positioned cuts in DNA. Harnessing the natural mechanisms for repairing breaks in DNA found in every cell, these ‘molecular scissors’ can be used to remove, alter or replace small sequences of DNA; the changes resulting from the operation can be examined either in single cells in culture or in whole organisms. The most effective of these editing tools, known as CRISPR-Cas9, is derived from a natural immune defence mechanism found in bacteria and in the past two years has been adapted for use in a variety of organisms and with wide applications in research, medicine and crop breeding (Emmanuelle Charpentier , Max Planck Institute, Berlin, Germany). It provides a rapid way to examine the sea of variations in gene sequences between individuals and to identify those that cause problems, which will be of fundamental importance in personalised medicine (Zhang ).

The rest of the presentations focused on the applications of CRISPR-Cas9 and other editing methods in nervous system development, function and disease. In development, gene editing is enabling the study of the dynamics of gene regulation in real-time in single cells as they become differentiated into specific functional types (Jaenisch ). Rapid genomic screening of neural stem cells is giving an insight into vulnerability to mental illness: genes associated with establishing neural connections and synaptic function contain breaking regions in the DNA that are susceptible to stress (Frederick Alt , Children’s Hospital, Harvard Medical School, Boston, USA). The study of fish brains is contributing to understanding how nervous systems regenerate. Because they grow throughout life, these brains contain populations of active stem cells, which can be manipulated with tools such as CRISPR-Cas9 to provide information about the conditions controlling cell division in the generation of new neurons (Jean-Stéphane Joly , CNRS/INRA, University Paris-Saclay, Gif-sur-Yvette, France).

Much has already be learned about synaptic function with the now-old-fashioned methods of gene silencing but use of CRIPSR-Cas 9 is allowing a far more refined dissection of molecular mechanisms. Molecules previously thought to be active only when synaptic function changes during memory formation are now being found also to have an essential role in the on-going maintenance of the synapses of some neurons (Salvatore Incontro , University of California, San Francisco, USA). The CRISPR-Cas 9 method is also being applied on the whole-cell level in zebra fish to study how neural circuits become hooked-up during development. Specific types of neurons can be identified by genetic targeting of protein markers, which can be visualised in real time as the fish larva are almost transparent (Filippo del Bene , Institut Curie, Paris, France).

Genome editing adds an extra layer of sophistication to another already powerful biomedical research tool, induced pluripotent stem cells (iPSCs have been the topic of two previous Fondation Ipsen meetings: Programmed cells : from basic neuroscience to therapy, Paris, April 2012 and Stem cells in neuroendocrinology, Paris, December 2015. Skin cells taken from a patient can be made to revert to undifferentiated stem cells in vitro and now CRISPR-Cas9 is being used to correct disease-related genetic defects before the stem cells undergo differentiation into particular cell types, with the ultimate goal of replacing the patient’s damaged cells. Such stem cells are being used for investigating the effects of specific, disease-related mutations by creating isogenic cell lines: colonies of cells with identical genomes except that one has the normal copy of the gene, the other the mutated one. Application include determining the effects of genes that increase the risk of developing Parkinson’s disease on neuron function (Jaenisch ); examining the deficits in neuronal function related to mutations linked to autism (Neville Sanjana , Broad Institute, Cambridge, USA); investigating why myelin production is disrupted by the mutation that causes the fatal congenital Pelizaeus-Merzbacher disease (Marius Wernig , Institute for Stem Cell Biology and Regenerative Medicine, Stanford, USA); and determining why only certain types of neuron are susceptible to the mutant protein that causes Huntington’s disease (Lisa Ellerby , Buck Institute for Research on Aging, Novato, USA). Genetic screens of single cells are also being used to analyse how this mutant protein affects cell function (Myriam Heiman , MIT, Cambridge, USA).

A proof-of-principle experiment to bypass the gene defect causing Duchenne muscular dystrophy is having some success in mice, using a specially designed CRISPR-Cas9 to modify the mutant gene, a taste of future therapies for presently intractable genetic diseases (Amy Wagers , Joslin Diabetes Center, Harvard Medical School, Boston, USA). Bringing animal models closer to humans, the common marmoset, a primate that is both easy to breed and has close similarities to humans than the more commonly used macaque monkeys, is now being genetically modified to mimic symptoms of various human neurodevelopmental and neurodegenerative diseases (Hideyuki Okano , Keio University, Tokyo, Japan).

The meeting provided a snapshot of this fast growing field, a taste of the wide range of creative ways in which these genome-editing tools are being applied, and a look to their future use in the development of personalised medicine.

About the Fondation Ipsen
Established in 1983 under the aegis of the Fondation de France, the mission of the Fondation Ipsen is to contribute to the development and dissemination of scientific knowledge. The long-standing action of the Fondation Ipsen aims at fostering the interaction between researchers and clinical practitioners, which is indispensable due to the extreme specialization of these professions. The ambition of the Fondation Ipsen is to initiate a reflection about the major scientific issues of the forthcoming years. It has developed an important international network of scientific experts who meet regularly at meetings known as Colloques Médecine et Recherche , dedicated to three main themes: neurosciences, endocrinology and cancer science. Moreover the Fondation Ipsen has started since 2007 several meetings in partnership with the Salk Institute, the Karolinska Institutet, the Massachusetts General Hospital, the Days of Molecular Medicine Global Foundation as well as with the science journals Nature , Cell and Science . The Fondation Ipsen produced several hundred publications; more than 250 scientists and biomedical researchers have been awarded prizes and research grants.
www.fondation-ipsen.org

Contact:

Image Sept
Isabelle de Segonzac,Tel. : +33 (0)1 53 70 74 70
E-mail : isegonzac@image7.fr

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bybit Expands Partnership with Thredd to Globally Scale Multi-Currency Crypto-Linked Debit Cards30.10.2025 09:00:00 CET | Press release

Thredd, the leading next-generation global payments processor, today announced an expanded partnership with Bybit, the world’s second-largest cryptocurrency exchange by trading volume. The collaboration supports regional rollout of the Bybit Card—Bybit’s flagship multi-currency, crypto-linked payment card, bridging the gap between digital assets and everyday payments across key global markets. Thredd’s processing platform is built to scale and navigate regulatory requirements across regions. With a single connection, Bybit can configure market-specific programs that meet local compliance needs while retaining centralized visibility. This flexibility has enabled Bybit to rapidly expand across multiple markets with more on the horizon. Over 2 million users worldwide trust the Bybit Card for what matters most: competitive cardholder rewards, true global access, and effortless crypto-to-fiat convenience. Bybit leverages Thredd’s infrastructure to issue both virtual and physical Visa and Ma

Manhattan Associates Announces Appointment of Greg Betz As Chief Operating Officer30.10.2025 09:00:00 CET | Press release

Manhattan Associates Inc. (NASDAQ: MANH) today announced the appointment of Greg Betz to the position of Chief Operating Officer. A seasoned executive, Betz brings broad experience leading complex, international organisations. Most recently, Greg led Microsoft FastTrack, an organisation of more than 1,000 engineers in 35 countries that deliver cloud conversions to Microsoft's largest cloud customers. “Greg is an accomplished executive with a proven track record of delivering operational excellence to transform businesses and drive growth,” said Eric Clark, president and CEO of Manhattan Associates. “His appointment is yet another proof point of our commitment to expanding the depth and experience of our team to drive faster cloud adoption, and I am confident that his forward-thinking, result-oriented approach will play a pivotal role in our next phase of rapid growth.” In his new position, Greg will play a key role in helping scale the operational frameworks around conversions and rene

Coats Completes Acquisition of OrthoLite, Strengthening Footwear Business30.10.2025 08:15:00 CET | Press release

Acquisition aligns with Coats’ Long-Term Growth Strategy in Apparel and Footwear Coats Group plc, a world-leading Tier 2 supplier of critical components to the apparel and footwear industries, announced today that it has completed its acquisition of OrthoLite, a global market leader in footwear materials and the number one brand in premium insoles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030015142/en/ OrthoLite Vietnam The acquisition marks a major milestone in the Company’s long-term growth plans and strengthens its existing footwear division through expansion into the attractive, high-growth premium insole segment. Both companies already have a similar customer base, a complementary global footprint and a commitment to industry-leading innovation and sustainability practices. “OrthoLite is one of the world’s most innovative manufacturers in footwear materials. With our combined capabilities, we’ll now be able to

Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year30.10.2025 08:04:00 CET | Press release

First Half Revenue Declined 3.9% at Constant Exchange Rate (CER), -6.9% atActual Exchange Rates (AER),Impacted by Generic Erosion of VYVANSE® and FX HeadwindCore Operating Profit Declined 8.8% at CER in the First Half, Reflecting Revenue Performance and Product Mix; Impact Partially Offset by Operational EfficienciesFirst Half Reported Operating Profit (-27.7% at AER) Impacted by Impairment Losses Incurred in Q2 Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first half of fiscal year 2025 (six months ended Sep 30, 2025) and updated its full-year outlook. Takeda chief executive officer, Christophe Weber, commented: “Takeda’s fiscal year 2025 first half results are consistent with our expectations for core business progress in this year of transition to a new phase focusing on new product launches. Our updated full-year outlook reflects impairment charges associated with strategic pipeline decisions taken in Q2, as well as transactional FX. “Looking ahead, our curr

Aduna, Deutsche Telekom, mBank and Vonage Join Forces at World Banking Forum to Showcase the Future of Banking Security30.10.2025 08:00:00 CET | Press release

This powerful industry collaboration highlights how mobile networks, APIs, and AI can transform banking Vonage, a part of Ericsson (NASDAQ: ERIC), today announced that, together with leaders from Aduna, Deutsche Telekom, and mBank, it is participating in the World Banking Forum in Athens. The event convenes senior banking executives and technology leaders from around the world to advance modern banking through technology innovation and digital transformation. An increase in fraud has emerged from the rise of digital channels in financial services and continues to evolve and grow with new technologies such as AI that enable more sophisticated threats. As cyber threats continue to escalate and regulations tighten, it is more critical than ever for banks to deploy advanced fraud protection strategies. Cybercrime damages are projected to reach $11.9 trillion annually by 2026 and technology innovation is needed to meet regulatory demands and strengthen a financial institution's overall frau

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye